Search results for: Multi-Indication Medicines
Filter search results
OHE’s submission to a parliamentary inquiry on UK drug shortages
6 October 2025
…concern, becoming more commonplace, and lasting longer. They affect multiple therapeutic areas but are often concentrated in generic and biosimilar markets. Cost-containment policies can result in very low prices being…
Around the World in HTAs: Spain – Closer than ever, but not quite yet
8 July 2026
…reforms – a draft Royal Decree on medicines pricing and reimbursement and a new Medicines and Medical Devices Bill – are still moving through the policy pipeline. Together, these texts…
Multinational Evidence of the Applicability and Robustness of Discrete Choice Modeling for Deriving EQ-5D-5L Health-State Values
13 January 2015
Published in Medical Care [open access] is a paper reporting a multi-country pilot study investigating the feasibility of using discrete choice experiments (DCE) to value EQ-5D-5L health states. Published in…
One Europe, one assessment? Unpacking the European Joint Clinical Assessment
28 May 2026
…national level, that has already been submitted at the EU level. Abbreviations: AIFA, Italian Medicines Agency; DMC, Danish Medicines Council; G-BA, Federal Joint Committee; HAS, French National Authority for Health; HTAR, Regulation (EU) 2021/2282 on…
Time Trends in NICE HTA Decision Making: Setting the Record Straight
21 May 2012
…remit to appraise all medicines when they are launched (in comparison to the Scottish Medicines Consortium, for example). Instead, the medicines that NICE considers are chosen by the Department of…
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a Central Role for Value Assessment
8 April 2019
…key to efficient pricing and use of cancer medicines. The Research Paper outlines some for addressing these shortcomings. A new OHE Research Paper by Simon Brassel, Olga Rozanova, and Adrian…
Price Transparency: Good or Bad? What Does Literature and Theory Tell Us?
17 March 2020
…one-sided disclosure of multi-source prices, i.e., buyers sharing price data for off-patent medicines amongst themselves. It would require databases of ex-factory off-patent prices employing strong security protocols to prevent supplier…
Narrowing the Gap between provision and need for medicines in developing countries
1 February 2000
…need and the probability of success (a function of the state of science, in-house resources and experience and risk). As the expected number of patients able to pay for medicines…
Around the world in HTAs: Abu Dhabi – Advancing HTA and value-based healthcare in the UAE
1 July 2026
…by applying these modifiers multiplicatively to the baseline threshold: CET = 0.75 × GDP per capita × (1 + PS) × (1 + RHG) × (1 + 2 × is_rare) This multi-factor, multiplicative threshold design allowed for a…